Relieving the Burden
The EMA recommends MSD’s Ebola vaccine for approval
Maryam Mahdi | | Quick Read
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting a conditional marketing approval for Merck Sharp & Dohme’s Ebola vaccine, Ervebo. The vaccine was first developed by NewLink Genetics and licensed to MSD in 2014. According to the EMA, the active substance of Ervebo consists of a live attenuated recombinant Vesicular stomatitis virus (rVSV), which has its VSV envelope glycoprotein replaced with the Zaire ebolavirus (ZEBOV) surface glycoprotein (1). The vaccine is indicated for use in adults aged 18 or over against the Zaire strain of the Ebola virus, which was responsible for the 2014-2016 outbreak in West Africa.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.